section name header

Evidence summaries

Olanzapine and Risk of Diabetes

Olanzapine may increase the risk of diabetes. Level of evidence: "C"

A population based nested case-control study 1 comprised a total of 19 637 patients who had been diagnosed as having and treated for schizophrenia. A total of 451 incident cases of diabetes were matched with 2696 controls.

Patients taking olanzapine had a significantly increased risk of developing diabetes than non-users of antipsychotics (odds ratio 5.8, 95% confidence interval 2.0 to 16.7) and those taking conventional antipsychotics (4.2, 1.5 to 12.2).

The following decision support rules contain links to this evidence summary:

    References

    • Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002 Aug 3;325(7358):243. [PubMed]

Primary/Secondary Keywords